spark therapeutics ticker
Fundamental company data provided by Zacks Investment Research. The company was founded in 2013 by Katherine A. View the latest Spark Therapeutics Inc. (ONCE) stock price, news, historical charts, analyst ratings and financial information from WSJ. Only 6.00% of the stock of Spark Therapeutics is held by insiders. Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. On Tuesday, shares of Spark Therapeutics recorded a trading volume of 646,612 shares, which was above the three months average volume of 560,567 shares. There are currently no items in this Watchlist. Tickers BMRN ESRX ONCE. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Gene-Therapy Firm Audentes Sells for Double Its Share Price. Export data to Excel for your own analysis. We create the path. Cookie Notice (). “Today ushers in a new and promising era in the development of genetic medicines for patients and families living with inherited diseases and beyond,” said Jeffrey D. Marrazzo, co-founder and CEO of Spark Therapeutics. Please log in to your account or sign up in order to add this asset to your watchlist. Roche purchases shares in tender offer for Spark Therapeutics, Inc. Roche intends to complete Spark acquisition today ; Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and … Spark Therapeutics, Inc is primarely in the business of biological products (no diagnostic substances). Learn about financial terms, types of investments, trading strategies and more. An invaluable data source for traders & investors looking to familiarize themselves with the Roche (RHHBY) takeover of Spark Therapeutics (ONCE) and trade the merger arbitrage spread.Following the acquisition news and events section, there is in-depth company profile. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE.". Could pandemic bring biotech businesses to Jupiter? Spark Therapeutics Inc (NASDAQ:ONCE) announced its earnings results on Tuesday, August, 7th. We use our genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Learn everything you need to know about successful options trading with this three-part video course. Tickers BMRN ESRX ONCE. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. You may vote once every thirty days. View Spark Therapeutics' earnings history. Vote “Underperform” if you believe ONCE will underperform the S&P 500 over the long term. Their latest funding was raised on May 27, 2014 from a Series B round. ), Spark Therapeutics has received 443 “underperform” votes. Some companies that are related to Spark Therapeutics include Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), Novavax (NVAX), QIAGEN (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Acceleron Pharma (XLRN), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Vir Biotechnology (VIR), Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT). The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. In the past three months, Spark Therapeutics insiders have not sold or bought any company stock. The Stock Performance of Spark Therapeutics, Inc, is significantly lower than the stock performance of its index. Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law. There is not enough analysis data for Spark Therapeutics. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.34.
Price to Earnings Ratio vs. Sector Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Feb 25, 2019 11:37 AM EST. January 03, 2018. Our ONCE ETF report shows the ETFs with the most ONCE exposure, the top performing ONCE ETFs, and most popular ONCE ETF strategies. Spark Therapeutics is funded by 7 investors. The biotechnology company had revenue of $25.19 million for the quarter, compared to analysts' expectations of $29.44 million. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. Spark Therapeutics had a negative trailing twelve-month return on equity of 59.10% and a negative net margin of 358.41%. Earnings for Spark Therapeutics are expected to grow in the coming year, from ($5.07) to ($4.34) per share. January 16, 2018. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Historical and current end-of-day data provided by FACTSET. Kristine Harjes: First, Spark Therapeutics, ticker ONCE, lost 28% of its market cap on Tuesday of last week. Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. We don’t follow footsteps. Spark Therapeutics is headquartered at 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. We were born of innovation, springing from the curiosity, imagination and dedication of remarkable scientists and healthcare visionaries. Feb 25, 2019 11:37 AM EST. Spark Therapeutics is an equal opportunity employer. An estimated 5,000 rare diseases are each caused by a single … J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. From Benzinga. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Pfizer (PFE) and (CELG). Create a list of the investments you want to track. Subscriber Agreement & Terms of Use,
Spark Therapeutics files for an IPO by David Sell, Inquirer Staff Writer , Posted: December 31, 2014 Spark Therapeutics Inc., which hopes to turn decades of gene-therapy research at Children's Hospital of Philadelphia into commercial cures for diseases, has … MARKETS. | At Spark Therapeutics, we don’t follow footsteps. January 16, 2018. Stock analysis for Spark Therapeutics Inc (ONCE) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Spark Therapeutics Inc., which hopes to turn decades of gene-therapy research at Children's Hospital of Philadelphia into commercial cures for diseases, has filed papers to conduct an initial public stock offering. (Add your “outperform” vote. Spark a change in your career and join us! Kristine Harjes: First, Spark Therapeutics, ticker ONCE, lost 28% of its market cap on Tuesday of last week. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Want to see which stocks are moving? The tool is limited to U.S. common equities listed on U.S. stock exchanges. The P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Visit a quote page and your recently viewed tickers will be displayed here. Their latest funding was raised on May 27, 2014 from a Series B round. An invaluable data source for traders & investors looking to familiarize themselves with the Roche (RHHBY) takeover of Spark Therapeutics (ONCE) and trade the merger arbitrage spread.Following the acquisition news and events section, there is in-depth company profile. The company's product candidates are in the field of retina-directed gene therapies, liver-directed gene therapies, and central nervous system therapies. By Martin Baccardax. MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Tags Price Target Analyst Color Blindness. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The stock ended the day 8.07% higher at … Spark Therapeutics' management team includes the following people: Co-Founder, Pres, Head of R&D and Director, Start Your Risk-Free Trial Subscription Here, Attack on Saudi oil site fuels upward march for crude prices, Spanish food delivery riders want right to be self-employed, Stocks rise broadly on Wall Street even as technology lags, Airline stocks rally, American cites plan to pay off loan, Meme fav GameStop jumps again as retailer eyes digital shift, Cyprus, Israel, Greece sign deal on electric cable link, Great Time to Buy Goodyear Tires (NYSE: GT) Stock Here, Here’s Where the S&P 500 (NYSEARCA: SPY) Can Go From Here, Xpeng, Inc (NYSE:XPEV) Is Loaded For Growth, Vuzix Eyeing Partnerships For Its Augmented Reality Glasses, The Children’s Place Could Benefit From a Post-Vaccine Baby Boom, V.F. The P/E ratio of Spark Therapeutics is -53.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The price change percentage of Spark Therapeutics, Inc, over the last month is N/A%. Learn more. Spark Therapeutics, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Will Editas Medicine's CEO Change Help or Hurt? Vote “Outperform” if you believe ONCE will outperform the S&P 500 over the long term. Despite … MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Annual stock financials by MarketWatch. For the best MarketWatch.com experience, please update to a modern browser. To see all exchange delays and terms of use please see disclaimer. Spark Therapeutics has received 53.95% “outperform” votes from our community. ONCE investors should pay attention to a decrease in hedge fund interest of late. Shares in Spark Therapeutics Inc are currently trading at $113.57 and the price has moved by 0.183k% over the past 365 days. Have Watchlists? Intraday Data provided by FACTSET and subject to terms of use. Spark Therapeutics is registered under the ticker NASDAQ:ONCE . By using this site you agree to the
Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases. Tickers ONCE. Watch out for more sell signals from this stock market, Stay short-term bullish as the S&P 500 tests its all-time highs, U.K.’s Competition watchdog opens probe into Roche takeover of Spark Therapeutics, S&P 500 bulls are in control for now, but don’t overcommit to the upside just yet, These battered biotech stocks are now buying opportunities as Elizabeth Warren climbs in the polls, 2 reasons to remain bullish on the stock market, Don’t stand in the way of this bull market in stocks, How to trade the S&P 500’s breakout from its long-standing trading range, The stock market is going nowhere right now, CRISPR gene-editing technique set to push new boundaries, S&P 500’s technical indicators say be cautious, Hold on to your core bearish stock-market position, S&P chart stays bullish, so don’t bail out yet, Keep rolling with the new stock-market highs, The stock market will keep charging ahead, GAMCO Investors Exits Viacom, Spark Therapeutics, Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More, John Paulson's Top 5 Buys in the 3rd Quarter.